Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis

Research output: Contribution to journalJournal articleResearchpeer-review

  • K U Sales
  • S Friis
  • J E Konkel
  • S Godiksen
  • M Hatakeyama
  • K K Hansen
  • S R Rogatto
  • R Szabo
  • Vogel, Lotte
  • W Chen
  • J S Gutkind
  • T H Bugge
The membrane-anchored serine protease, matriptase, is consistently dysregulated in a range of human carcinomas, and high matriptase activity correlates with poor prognosis. Furthermore, matriptase is unique among tumor-associated proteases in that epithelial stem cell expression of the protease suffices to induce malignant transformation. Here, we use genetic epistasis analysis to identify proteinase-activated receptor (PAR)-2-dependent inflammatory signaling as an essential component of matriptase-mediated oncogenesis. In cell-based assays, matriptase was a potent activator of PAR-2, and PAR-2 activation by matriptase caused robust induction of nuclear factor (NF)κB through Gαi. Importantly, genetic elimination of PAR-2 from mice completely prevented matriptase-induced pre-malignant progression, including inflammatory cytokine production, inflammatory cell recruitment, epidermal hyperplasia and dermal fibrosis. Selective ablation of PAR-2 from bone marrow-derived cells did not prevent matriptase-driven pre-malignant progression, indicating that matriptase activates keratinocyte stem cell PAR-2 to elicit its pro-inflammatory and pro-tumorigenic effects. When combined with previous studies, our data suggest that dual induction of PAR-2-NFκB inflammatory signaling and PI3K-Akt-mTor survival/proliferative signaling underlies the transforming potential of matriptase and may contribute to pro-tumorigenic signaling in human epithelial carcinogenesis.Oncogene advance online publication, 27 January 2014; doi:10.1038/onc.2013.563.
Original languageEnglish
JournalOncogene
Volume34
Issue number3
Pages (from-to)346-356
Number of pages11
ISSN0950-9232
DOIs
Publication statusPublished - 15 Jan 2015

ID: 108671517